HLS Therapeutics Inc. HLS.TO
Nov 4, 2026, 12:22 PM EST
- YTD
- -10.37%
- 1 year
- -20.30%
- Market cap
- 133.64M
- Revenue (ttm)
- 56.94M
- Profit margin
- -38.70%
- EPS (ttm)
- -0.39
- Shares out
- 31.79M
- Forward P/E
- -7.50
- YTD return
- -10.37%
- 1-year return
- -20.30%
- Volume
- 2.97K
- Avg volume
- 73.91K
- Open
- 4.49
- Previous close
- 4.23
- Day's range
- 4.30 – 4.49
- 52-week range
- 0.001 – 5.44
- Beta
- 1.07
- Price target
- 6.09 (+41.0%)
2Y +1.06 (+32.12%)
Key statistics
- Enterprise value
- 173.16M
- PEG ratio
- 0.00
- Price / sales
- 2.09
- Price / book
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -12.20%
- Free cash flow
- 27.20M
- Total cash
- 17.54M
- Total debt
- 68.62M
- Return on equity
- -24.33%
- Short % of float
- 0.00%
- 50-day average
- 3.54
- 200-day average
- 3.70
Analyst view
- Target (low)
- 3.61
- Target (mean)
- 6.09
- Target (high)
- 9.81
- Strong buy0
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.09.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 18, 2024 | Raymond James | main | Market Perform | Market Perform |
| Aug 6, 2021 | Raymond James | down | Outperform | Market Perform |
About HLS Therapeutics Inc.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- hlstherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on HLS.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Canoe Financial LP | 1.54% | 499,001 | 1.87M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DFA Investment Dimensions-Canadian Small Company Series | 0.06% | 20,104 | 75.39K | Jul 30, 2024 |
| Highland Fds II-Highland Global Allocation Fd | 0.03% | 10,445 | 39.17K | Sep 29, 2024 |
| DFA Investment Dimensions-DFA Va International Small | 0.01% | 2,903 | 10.89K | Jul 30, 2024 |
| DFA Investment Dimensions-World Ex U.S. Core Equity Port | 0.01% | 2,000 | 7.50K | Jul 30, 2024 |
| Lincoln VIP Tr-Dimensional International Core Equity Fd | 0.01% | 2,317 | 8.69K | Sep 29, 2024 |
| John Hancock Fds II-International Small Company Fund | 0.01% | 2,600 | 9.75K | Oct 30, 2024 |